Controlled trial of ornithine alpha ketoglutarate (OAKG) in patients with stroke.

Abstract

A double blind controlled trial of ornithine alpha-ketoglutarate (OAKG) was carried out on 50 patients admitted to the Royal Free and Royal Northern Hospitals, London, suffering from a recent stroke. Significant improvement was found in patients treated with OAKG when examined on the fifth day of therapy as compared to their control cases. The therapy was given for 5 days. When the patients in the treated and the control groups were compared 10 days after the beginning of treatment, there were no differences between the 2 groups. Implications of these findings are discussed.

• Authors: M L Woollard, R M Pearson, G Dorf, D Griffith, I M James
• Journal: Stroke (Stroke) 1978 May-Jun Vol. 9 Issue 3 Pg. 218-22 ISSN: 0039-2499 [Print] United States
• PMID: 347638 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Ketoglutaric Acids
• ornithine alpha-ketoglutarate
• Ornithine

Topics

• Aged
• Cerebrovascular Disorders (drug therapy, physiopathology)
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Humans
• Ketoglutaric Acids (therapeutic use)
• Male
• Middle Aged
• Ornithine (analogs & derivatives, therapeutic use)
• Time Factors